The term “off-label” is described by the FDA as an unapproved use of an approved drug. Recently, a study conducted at Kaiser Permanente Colorado found that off-label uses of Rituximab, particularly to treat demyelinating neurologic diseases, now account for more than...
Multiple Sclerosis
Category
Duke Participates in the BEAT-MS Clinical Trial Comparing Stem Cell Transplantation to Immunotherapy
Duke University, through the Immune Tolerance Network, is offering a multicenter, Phase III interventional clinical trial examining the efficacy of autologous hematopoietic stem cell transplantation, an emerging therapy for patients with active, treatment-resistant,...
Monash University Investigators One Step Closer to Novel Treatment for MS
Monash University investigators are in pursuit for a new treatment for multiple sclerosis (MS) that they believe may actually reverse effects of the disease on the brain. They are exploring the use of an experimental drug called Dipta. During preclinical research on...
Trinity College Dublin New Discovery Offers Hope for Improved MS Therapies in The Future
Researchers from Trinity College Dublin have made an important discovery that may lead to more effective multiple sclerosis (MS) treatments as well as other autoimmune diseases such as psoriasis and rheumatoid arthritis. They are focused on drugs centering on IL-17, a...
GeNeuro Secures €17.5 million in the Nick of Time for MS Clinical Trial
GeNeuro, a European biopharmaceutical company developing new treatments, focused on stopping causal factors driving the progression of neurodegenerative and autoimmune disease raised €17.5 million ($19.3 million) international private placement to certain qualified...
Short Sellers Pursue Principia Biopharma Arguing the Addressing Autoimmune Disease with BTK Inhibitors Flawed Strategy
Boutique short-seller Kerrisdale Capital Management (KCM), a private investment manager, recently published a report explaining why they have taken a short position in Principia Biopharma Inc. (NASDAQ: PRNB), a biopharma company whose recent $2 billion valuation is...
Case Western Reserve University Researchers Developed Myeliviz, Heads to Phase I Clinical Trial for MS
Case Western Reserve University researchers have developed a drug known as Myeliviz that could make it easier for doctors to diagnose multiple sclerosis (MS) in its earlier stages. The Ohio-based team has secured $1.7 million from the NIH for an FDA-compliant...
OMRF Investigates Dimethyl Fumarate on Use for Multiple Sclerosis
Oklahoma Medical Research Foundation (OMRF) researchers are investigating how an FDA—approved multiple sclerosis drug affects vision loss. It so happens that vision loss is one of the most common symptoms of the disease. Multiple Sclerosis A complex autoimmune...
Immune Tolerance Network Launches Cell Therapy vs. Standard of Care Clinical Trial for Multiple Sclerosis Patients
The Immune Tolerance Network (ITN) has opened the BEAT-MS clinical trial for patient enrollment. BEAT-MS or “Best Available Therapy vs. Autologous Hematopoietic Stem Cell Transplant (AHSCT) for MS” will investigate high dose immunosuppression followed by AHSCT—a type...
OMRF Multiple Sclerosis Clinical Trial Makes Big Difference in Patient’s Life
Diagnosed with multiple sclerosis (MS), Tonja Martin was in trouble. Biologics drugs that are available to help stave off the disease cost $40,000 or more per year. Tonja’s insurance wouldn’t cover her prescription, and she had to start using her retirement savings....
Mount Sinai Medical Center Recruited as Site for Autologous MSC-NTF Cell Study for MS Patients
Mount Sinai Medical Center, internationally acclaimed for its excellence in research, patient care, education in multiple sclerosis and a range of medical specialties, was recruited by clinical sponsor BrainStorm Cell Therapeutics, Inc (BCLI) as a clinical trial site...
Karolinska Institutet & Academic Specialist Center Sweden to Launch Clinical Trial for Temelimab in MS Patients
The Karolinska Institutet and the Academic Specialist Center (ASC), Stockholm, Sweden will conduct a clinical trial of temelimab in multiple sclerosis (MS) with commercial sponsor GeNeuro. Led by Dr. Fredrik Piehl, Professor of Neurology, Department of Clinical...
Memorial Healthcare Investigator Focuses on Biomarkers to Track & Evaluate Multiple Sclerosis Treatments
Dr. Rany Aburashed at Memorial Healthcare Https://www.memorial healthcare.org/ in Owosso, Michigan is conducting new research in a quest to find ways to stop the progression of Multiple Sclerosis. A local newscast reported on some recent evidence of success. Multiple...
$14.6 Million in Awards Granted to 43 Multiple Sclerosis Projects by National MS Society
The National Multiple Sclerosis Society (NMSS) awarded $14.6 million in grants supporting 43 new and multiyear research projects into multiple sclerosis (MS), part of a projected $36 million investment in disease research for 2019, the society announced on its...
University of Regina’s Trojan Horse Strategy Targeting Multiple Sclerosis
The Western Canadian plains of Saskatchewan are vast and expansive, and, at times, it would appear life moves fairly slow there. Named after “the swiftly flowing river” Saskatchewan is a hotbed for Multiple Sclerosis cases. The University of Regina represents a nexus...
Boston Children’s Hospital Investigators Identifies Promising Antibody Targeting Multiple Sclerosis
“Helper” T cells are white blood cells that launch an inflammatory attack on the brain and spinal cord when a person has multiple sclerosis, an autoimmune disorder. Boston Children’s Hospital pinpoints the specific subgroup of help T cells that cause MS, as well as...
Harry Potter Author Donates £15.3m to Support MS Center at the University of Edinburgh
Author JK Rowling has donated £15.3m to support neurological research at a center named after her mother. The Anne Rowling Regenerative Neurology Clinic at the University of Edinburgh was established with a £10m donation from the Harry Potter author in 2010. The...
Janssen’s Phase 3 OPTIMUM Study Meets Endpoint of Ponesimod Superiority Versus Aubagio in Adults With Relapsing Multiple Sclerosis
Janssen presented results from the Phase 3 OPTIMUM study for ponesimod, showing superior efficacy on the primary endpoint and most secondary endpoints compared to Aubagio (teriflunomide) in adults with relapsing multiple sclerosis (MS). The results were presented at...
Swiss Biotechnology Company Anokion SA Achieves Major Acquisition and Funding, Providing Runway for Multiple Emerging Autoimmune Therapies
Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the acquisition of Kanyos Bio, Inc. and the completion of a $40 million Series B financing. Anokion has come a long way, according to...
Oregon Health and Science University Pursues Multiple Sclerosis Vaccine in Primates in Anticipation of Human Trials
Oregon Health and Science University (OHSU) will initiate a preclinical research project centering on multiple sclerosis (MS). Apparently, some Japanese snow monkeys at its preclinical labs actually were diagnosed with a disease to similar to MS. The monkeys...